Dhaka, April 30 -- Despite registering strong revenue growth, Square Pharmaceuticals saw a marginal decline in profit in the January-March quarter this year, weighed down by higher operating expenses and a rising tax burden.

The country's largest drug manufacturer posted an 8 per cent year-on-year increase in revenue in the quarter, while profit edged down 1.32 per cent to Tk 5.97 billion in Q3 of FY26 compared to the same period last year.

Consequently, consolidated earnings per share (EPS) slipped to Tk 6.73 in the quarter ending March, from Tk 6.83 in the same period a year earlier, according to the company's unaudited financial statements published on Wednesday.

Financial disclosures show that operating expenses rose 12 per cent ye...